Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LI-2242
Cat. No.:
OB0425LY-182
Appearance:
Solid
Purity:
98.95%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor that inhibits IP6K1, IP6K2, IP6K3 and IPMK.
Synonyms:
LI 2242; 2762762-17-2; LI2242
CAS No.:
2762762-17-2
Compound CID:
163399353
Formula:
C20H18Cl2N2O3
Formula Weight:
405.27
Specification
Target:
IPK superfamily
Pathway:
Metabolic enzyme/Protease; PI3K/Akt/mTOR
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
LI-2242 can be used in studies of type II diabetes, obesity, and psychiatric disorders.
